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Abstract
In lieu of an abstract, below is the first paragraph of the paper.
The desire for mind and body enhancement may be intrinsic to human nature. Individuals continually engage
in behaviors like eating, exercising, or using chemicals such as caffeine or alcohol, in an effort to enhance mind
and body for personal desire. The principle of autonomy and free will allows the individual the right to
selfdetermination, freedom, and independence, although it is not an absolute right (Aiken, 2004). A healthy
person can choose medical treatments like sildenafil citrate (Viagra) or more invasive treatments like cosmetic
surgery to achieve personal outcomes. Neuroscience, or cosmetic neurology, uses pharmacological
interventions such as selective serotonin reuptake inhibitors (SSRIs) and stimulants to enhance brain
functioning by altering the neurotransmitters that affect mood and cognition. Cosmetic neurology by its
nature is more complex than self-medicating at Starbucks.
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The desire for mind and body enhancement 
may be intrinsic to human nature. Individuals 
continually engage in behaviors like eating, 
exercising, or using chemicals such as caffeine or 
alcohol, in an effort to enhance mind and body for 
personal desire. The principle of autonomy and 
free will allows the individual the right to self-
determination, freedom, and independence, 
although it is not an absolute right (Aiken, 2004). 
A healthy person can choose medical treatments 
like sildenafil citrate (Viagra) or more invasive 
treatments like cosmetic surgery to achieve 
personal outcomes. Neuroscience, or cosmetic 
neurology, uses pharmacological interventions 
such as selective serotonin reuptake inhibitors 
(SSRIs) and stimulants to enhance brain 
functioning by altering the neurotransmitters that 
affect mood and cognition. Cosmetic neurology by 
its nature is more complex than self-medicating at 
Starbucks. 
Neuroethics is concerned with three primary 
issues: safety, social effect, and philosophical 
aspects of individuals and values (Farah, 2004). It 
has the potential to alter social norms and how 
providers practice medicine (Fowler, 2004). The 
use of pharmacological agents in the healthy 
person to alter cognitive functions in the pursuit of 
intellectual and affective enhancement has ethical 
implications for society and human nature and 
worth (Wolpe, 2002). The dilemma in using 
medications to alter mood and cognition questions 
the ethics of treating the quality of an individual's 
life with the same method we treat a pathology. In 
other words, science needs to determine what is a 
medicine and what is a drug, and differentiate 
between the patient with an illness and the 
consumer in need of fulfillment (Folwer, 2004). 
Brain enhancement drugs have treated 
psychiatric and thought disorders, resulting in 
positive outcomes for individuals and society. 
Court ordered central nervous system (CNS) 
interventions have been already implemented, for 
example reducing violent behavior with SSRIs and 
antiadrogen treatment for convicted sex offenders. 
SSRIs can be used for one to three years after an 
episode of depression to prevent relapse. 
Depending on one's perspective or practice model, 
maintenance treatment can be seen as either over-
prescribing or ensuring patient safety by 
preventing further acute episodes (Farah, 2004). 
Reports on modafinil (Provigil) indicate it can 
successfully treat some patients with narcolepsy 
and other sleep disorders. The Food and Drug 
Administration (FDA) approved modafinil in 1998 
when the U.S Army tested its use with sleep 
deprivation (Hall, 2003). Stimulants, like Ritalin, 
have been reported to raise the academic 
performance and Scholastic Assessment Test 
(SAT) scores in children. Parents and teachers also 
report positive outcomes in children related to 
improved academic performance when being 
treated with stimulants. Furthermore, a study on 
memory enhancing medications tested the memory 
of airplane pilots one month after emergency flight 
training and receiving donepezil (Aricept). It was 
found that the pilots receiving Aricept 
remembered their training better (Gazzaniga, 
2005). Current research on these medications is 
focused on enhancing the cognitive and memory 
function of people with Alzheimer's Disease 
(AD), mental retardation, and sleep deprivation 
(Hall, 2003). Cosmetic cognitive enhancement is 
not a theoretical argument, but it is a living ethical 
dilemma. These medications are prescribed to 
consumers and their impact on cosmetic use is 
aggressively being researched. 
Enhancement medications are affected by 
health care costs. Medications that affect mood 
and cognition are prescribed for a variety of health 
issues. However, in areas like neurology and 
mental health these drugs are used as primary 
medical interventions. Many patients with 
neuropsychiatric pathologies do not receive the 
care they need due to key issues of access and cost 
in health care. Insufficient or lack of mental health 
coverage places more burden of cost to the 
consumer (APA, 2005). The factors limiting 
access to care will then put cosmetic clients who 
cannot access the system at an affective and 
cognitive disadvantage. Because enhancement of 
the healthy individual is a cosmetic treatment, 
insurance companies probably will not cover these 
procedures. This would limit treatment to those 
who can afford it (Chatterjee, 2004). It could also 
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place individuals with low socioeconomic status at 
an even greater social disadvantage with education 
and employment (Farah, 2002). 
The potential ethical implication is then a 
violation of distributive justice or equal and fair 
access to health care for all (Aiken, 2004). Health 
care access, cost, and quality are the principle 
social concerns in neuroethics. Ethical concerns 
are based on who will choose to enhance brain 
functioning and who will not. Autonomy and the 
right for an individual to choose 
neuropharmacological interventions may pose a 
threat by changing the criteria on what is seen as 
normal brain function and therefore raise the 
standards of normalcy. For example, raising the 
standards of normalcy could impact competition to 
the point of requiring government regulations for 
drug policies like in competitive sports events to 
assure fair competition or a level playing field. 
The writer questions if the debate over 
neuropharmacological enhancement is an 
appropriate concern at this time. Those who are 
medically and psychologically ill, performing 
below baseline function due to pathology, cannot 
receive necessary care. Does neuroethics then 
implicate that elective treatments for smarter and 
happier brains have priority over treatments for 
illness or life and death issues? Although, it 
appears unlikely that individuals who innately 
have normal memory function will use memory 
enhancement drugs because when memory 
operates within normal limits, we adapt to that 
level of functioning to the extent it is integrated 
with psychological self-concept (Gazzangia, 
2005). 
A major concern in the pharmacology of brain 
enhancement is drug safety, pertaining to the long-
term effects and the potential complications. The 
prescribing and administration of enhancement 
drugs is also a potential problem. Some literature 
suggests that mood and cognitive enhancing drugs 
do not truly benefit the healthy person, but 
potentially negatively affect mental functioning 
later on in life (Farah, 2004). Although all 
medications have side effects, the long-term 
effects of cognitive enhancing drugs are 
undetermined. The research on drug safety does 
not always incorporate long-term use, and there is 
even less research on the long-term use in healthy 
individuals. Stimulant drugs like methylphenidate 
(Ritalin), used to treat Attention Deficit 
Hyperactive Disorder (ADHD), and modafinil also 
increase attention in healthy individuals. A 
concern with these drugs is long-term use may 
promote premature memory loss and cognitive 
decline (Farah, 2004). Furthermore, Ritalin has 
been reported to have a high abuse potential, and 
even as a controlled substance, it is readily 
available on college campuses. Coffee is also 
available on campus, and some research suggests 
that Ritalin and modafinil have equivalent if not 
poorer results than caffeine (Hall, 2003). 
The long term or delayed side effects are 
unknown for medications that improve memory 
function, for example the cholinesterase inhibitors 
currently used in Alzheimer's Disease (Chatterjee, 
2004). A potential complication in the use of 
memory enhancement drugs is the impact on 
mood. Some memories are connected to mood, 
and altering the individual's selective process of 
choosing what he/she forgets may also enhance 
sensitivity to pain (Wolpe, 2002). Memory 
enhancement drugs may also open doors to a new 
set of disorders by exposing an individual to 
traumatic memories that would have otherwise 
been repressed and risk dissociation (Gazzangia, 
2005). The potential side effects of increased pain 
sensitivity, psychological disorders, and damaged 
brain function in later years of life are serious and 
negative outcomes associated with cosmetic 
neurology. This may be interpreted as violations of 
the ethical principles nonmaleficence and 
beneficence by health care providers who 
prescribe these medications because of the 
potential side affects. 
Mood and cognitive enhancers are prescribed 
by neurologists, psychiatrists, primary care 
providers, and even advanced practice nurses. 
However, this may pose a threat to patient safety 
and violate principles of nonmaleficence and 
beneficence. Primary care providers who treat 
mood or cognitive disorders do not typically spend 
as much time with patients as mental health 
providers. The limited interactions primary care 
providers have with patients may not allow 
ongoing and supportive therapeutic relationships. 
This may result in the possibility of overlooking 
other comorbidities or psychiatric distress. Some 
research supports that primary care providers offer 
patients little information on side effects and 
inadequate explanation regarding the therapeutic 
effects of medication compared to mental health 
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clinicians (Nolan, Bradley, & Carr, 2004). In 
addition, primary care physicians have been found 
to treat mood disorders like depression 
inappropriately, for example starting at higher 
doses and not recommending therapy in 
conjunction with medical treatment (Nolan, 
Bradley, & Carr, 2004). There are also parents and 
teachers who push providers to prescribe stimulant 
drugs like Ritalin to children with behavior and 
attention problems or ADHD (Diller, 1998). 
Whether or not primary health care providers 
make prescribing and treatment errors, is 
prescribing by proxy in the scope of practice of 
teachers and parents? 
Current literature in neuroethics suggests that 
affective and cognitive enhancement is already 
taking place and is unstoppable (Gazzangia, 2005). 
Although the benefit of enhancement drugs to the 
healthy person is still in question, medications like 
Viagra have set the stage for public acceptance 
and access (Hall, 2005). There may be civil and 
criminal penalties that can be attached when a 
health care provider prescribes enhancement 
drugs, similar to when professionals prescribe 
drugs with unfavorable risk-benefit ratios to 
children and adults or if they provide an athlete 
with steroids (Brock, 1998). 
The question of cognitive enhancement raises 
philosophical and social questions related to the 
medicalizing of human productivity as well as the 
value and dignity of work (Farah, 2004). Cosmetic 
neurology has demonstrated its efficacy in the 
healthy person, as well as the potential side effects 
and associated problems like addiction and over-
prescribing. Individuals have a right to autonomy 
and self-determination, but this does not include 
unrestricted access to treatment. The ethical 
impacts are in evidence and perhaps suggest a 
more conservative approach to the application of 
its tenets. Like other methods we use to enhance 
and improve our bodies, cosmetic neurology will 
be an ethical violation for some and the magic 
bullet for others. 
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